Author

Consuelo Glenn

Observed name: C. Glenn

Institution: Pfizer (United States)

Observed institutions: Pfizer (United States), University of Washington, Seagen (United States)

OpenAlex ID: A5049944865

Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Safety and efficacy results from the safety run-in period of the phase 3 ECHELON-3 study.

2022 · Nancy L. Bartlett, Christopher A. Yasenchak, et al. · Journal of Clinical Oncology · 4

Association of Elevated Umbilical Cord Blood Creatine Kinase and Myoglobin Levels with the Presence of Cocaine Metabolites in Maternal Urine

1996 · Paul Roby, Consuelo Glenn, et al. · American Journal of Perinatology · 4

P1178: Brentuximab Vedotin in Combination With Lenalidomide and Rituximab in Patients With Relapsed/refractory Dlbcl: Safety and Efficacy Results From the Safety Run-in Period of the Phase 3 Echelon-3 Study

2022 · N. L. Bartlett, C. A. Yasenchak, et al. · HemaSphere · 1

Safety characteristics of brentuximab vedotin among patient subgroups: Insightsfrom pooled clinical trial database

2025 · Heather Ward, Wamiq Zaidi, et al. · Blood

Works count: 4

Citation count: 9

H-index: 2

I10-index: